Blueprint Historical Cash Flow
| BPMC Stock | USD 88.93 2.85 3.11% |
Analysis of Blueprint Medicines cash flow over time is an excellent tool to project Blueprint Medicines Corp future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Begin Period Cash Flow of 189.5 M or Depreciation of 12.2 M as it is a great indicator of Blueprint Medicines ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Blueprint Medicines Corp latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Blueprint Medicines Corp is a good buy for the upcoming year.
Blueprint |
About Blueprint Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Blueprint balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Blueprint's non-liquid assets can be easily converted into cash.
Blueprint Medicines Cash Flow Chart
Add Fundamental
Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Capital Expenditures
Capital Expenditures are funds used by Blueprint Medicines Corp to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Blueprint Medicines operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Most accounts from Blueprint Medicines' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Blueprint Medicines Corp current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Blueprint Medicines Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. At present, Blueprint Medicines' Depreciation is projected to increase significantly based on the last few years of reporting. The current year's Investments is expected to grow to about 149.1 M, whereas Change In Cash is projected to grow to (41.2 M).
| 2023 | 2024 (projected) | Sale Purchase Of Stock | 91.2M | 68.0M | Change To Liabilities | 4.1M | 3.9M |
Blueprint Medicines cash flow statement Correlations
Click cells to compare fundamentals
Blueprint Medicines Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Blueprint Medicines cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 46.2M | 570.2M | (474.7M) | (90.2M) | (43.4M) | (41.2M) | |
| Stock Based Compensation | 54.7M | 75.5M | 91.6M | 99.0M | 92.7M | 47.1M | |
| Free Cash Flow | (292.0M) | 383.9M | (559.9M) | (511.2M) | (452.9M) | (430.3M) | |
| Change In Working Capital | 9.7M | (15.6M) | (23.7M) | (53.8M) | (41.1M) | (39.1M) | |
| Begin Period Cash Flow | 73.4M | 119.6M | 689.8M | 215.1M | 124.9M | 189.5M | |
| Other Cashflows From Financing Activities | 340.6M | 35.3M | 50.7M | 424.0M | (44K) | (41.8K) | |
| Depreciation | 5.3M | 6.6M | 6.5M | 11.7M | 11.7M | 12.2M | |
| Other Non Cash Items | 5.0M | 6.2M | 269.6M | (1.7M) | 6.9M | 6.6M | |
| Capital Expenditures | 14.0M | 3.2M | 261.2M | 8.9M | 16.1M | 15.3M | |
| Total Cash From Operating Activities | (278.0M) | 387.0M | (298.7M) | (502.3M) | (436.8M) | (415.0M) | |
| Net Income | (347.7M) | 313.9M | (644.1M) | (557.5M) | (507.0M) | (481.6M) | |
| Total Cash From Financing Activities | 340.6M | 617.8M | 50.7M | 561.8M | 119.2M | 113.3M | |
| End Period Cash Flow | 119.6M | 689.8M | 215.1M | 124.9M | 81.5M | 77.4M | |
| Change To Liabilities | 38.4M | 15.4M | 10.3M | 3.6M | 4.1M | 3.9M | |
| Sale Purchase Of Stock | 5.3M | 6.1M | 340.8M | 79.3M | 91.2M | 68.0M | |
| Investments | (2.5M) | (431.1M) | 35.4M | (140.3M) | 142.0M | 149.1M | |
| Net Borrowings | (2.6M) | (1.7M) | 137.8M | 553.6M | 636.7M | 668.5M | |
| Total Cashflows From Investing Activities | (16.5M) | (434.2M) | (225.9M) | (149.5M) | (134.6M) | (141.3M) | |
| Change To Account Receivables | (599K) | (6.4M) | (18.1M) | 1.6M | (7.7M) | (7.3M) | |
| Change To Operating Activities | 31.6M | (1.4M) | 1.0M | (32.0M) | (28.8M) | (27.3M) | |
| Other Cashflows From Investing Activities | (2.5M) | (431.1M) | (258.2M) | (290K) | (261K) | (274.1K) | |
| Change To Netincome | 54.7M | 76.0M | 95.0M | 117.4M | 135.0M | 141.8M | |
| Cash And Cash Equivalents Changes | 46.2M | 570.5M | (473.8M) | (90.0M) | (81.0M) | (77.0M) | |
| Cash Flows Other Operating | (28.1M) | (11.7M) | 264.3M | (70.1M) | (80.6M) | (76.6M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Blueprint Medicines Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Blueprint Medicines' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Blueprint Medicines Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Blueprint Medicines Corp Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Blueprint Medicines Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Blueprint Medicines. If investors know Blueprint will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Blueprint Medicines listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.09) | Revenue Per Share 6.986 | Quarterly Revenue Growth 1.266 | Return On Assets (0.15) | Return On Equity (0.50) |
The market value of Blueprint Medicines Corp is measured differently than its book value, which is the value of Blueprint that is recorded on the company's balance sheet. Investors also form their own opinion of Blueprint Medicines' value that differs from its market value or its book value, called intrinsic value, which is Blueprint Medicines' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Blueprint Medicines' market value can be influenced by many factors that don't directly affect Blueprint Medicines' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Blueprint Medicines' value and its price as these two are different measures arrived at by different means. Investors typically determine if Blueprint Medicines is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Blueprint Medicines' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.